鉴定和优化结构-活性关系的dibromoacetophenones作为新型的mIDH1抑制剂
Cong Li1, Min Yang1, Zhiying Cui1
1School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chongqing University, Chongqing, 401331, PR China.
European journal of medicinal chemistry
|August 13, 2025
概括
研究人员开发了一种新型的双重抑制剂,针对癌症中常见的异酸脱酶1 (IDH1) 突变. 这种化合物,27j,表现出强大的IDH1和PDK1的抑制,减少瘤细胞的增殖和2-基酸盐的产生.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 生物化学 生物化学
背景情况:
- 在氨酸132中异酸脱酶1 (IDH1) 的突变经常在各种人类癌症中观察到.
- 这些IDH1突变导致基代谢物2-基酸盐 (2-HG) 的产生,驱动瘤发生.
- 向突变IDH1 (mIDH1) 是癌症治疗的一个有希望的治疗策略.
研究的目的:
- 发现和优化针对mIDH1和其他关键癌症相关激酶的新型双抑制剂.
- 评估化合物27j与mIDH1的体外和细胞活性及其下游影响.
- 评估27j对癌细胞增殖,细胞循环和细胞亡的表型影响.
主要方法:
- 内部化合物库的高通量选,以确定IDH1 R132H的初始抑制剂.
- 代结构-活性关系 (SAR) 研究,以优化化合物的效力和选择性.
- 生物化学测试以确定与野生类型和突变型IDH1/2和PDK1.2相比的IC50值.
- 细胞检测测量2-HG生产,细胞增殖,细胞周期分布和癌细胞系中的细胞亡.
- 在正常细胞系中进行细胞毒性评估.
主要成果:
- 化合物1-1显示了IDH1R132H的初始抑制 (73.6%在2μM).
- 优化化合物27j对IDH1 R132H和R132C表现出亚纳米级功效 (IC50分别为80.0和58.0nM),对野生型IDH1/2.2的活性最小.
- 化合物27j还抑制了PDK1 (IC50 = 0.61μM) 并根据剂量减少了PDH酸化.
- 在U87-MG IDH1 R132H和HT1080细胞 (EC50 = 69.0和121.1 nM) 中观察到显著抑制2-HG的产生.
- 在表型分析中,27j抑制了U87-MG IDH1 R132H细胞增殖 (GC50 = 1.4μM),诱导S相停止,并促进了细胞亡,对正常L02细胞的毒性有限.
结论:
- 化合物27j是一种强大的突变IDH1和PDK1的双重抑制剂.
- 27j有效地降低了代谢物2-HG水平,并抑制了癌细胞的增殖.
- 这些发现支持进一步开发27j作为IDH1-突变癌症的潜在治疗剂.
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.3K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.3K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
647
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
647
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.2K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.2K
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.4K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.4K
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
6.3K
All ortho–para directors, excluding halogens, are activating groups. These groups donate electrons to the ring, making the ring carbons electron-rich. Consequently, the reactivity of the aromatic ring towards electrophilic substitution increases. For instance, the nitration of anisole is about 10,000 times faster than the nitration of benzene. The electron-donating effect of the methoxy group in anisole activates the ortho and para positions on the ring and stabilizes the corresponding...
6.3K


